In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even ...

Africa bears a disproportionate infectious disease burden, with HIV, tuberculosis, and malaria posing ongoing threats ...

A FDA generic drug office was eliminated — and the implications will be felt not only by drugmakers, but consumers ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 - but only if between two and ...

A modelling study released in March gives a clue at which price the jab, lenacapavir, would be worth the health department’s ...

A modelling study shows that lenacapavir could end Aids in South Africa by 2032 – but only if between two and four million ...

NORTHAMPTON, MA / ACCESS Newswire / April 8, 2025 / In 2019, Somchai, a Thai native, was 21 years old and faced a double ...